Differentiated thyroid cancer: Ongoing monitoring

	Response to therapy
	Excellent	Biochemical incomplete	Structural incomplete	Indeterminate
Nonstimulated Tg	Every one to two years	Every six months	Every six months	6 to 12 months
Stimulated Tg	Not needed	May be repeated at two- to three-year intervals if needed to establish an excellent response to therapy	Not needed	May be repeated at two- to three-year intervals if needed to establish an excellent response to therapy
Neck ultrasound	Consider at three- to five-year intervals	Yearly for five years	Yearly for five years	6- to 12-month intervals for five years
Diagnostic WBS	Not indicated	Not usually done*	To evaluate RAI avidity of structural disease	Not usually done*
MRI, CT	Not indicated	Not indicated*	6- to 12-month intervals depending on rate of progression	Not indicated*
FDG-PET	Not indicated	Not indicated*	To identify additional sites of disease and for prognostic purposes	Not indicated*
Serum TSH^¶	0.5 to 2 mU/L	0.1 to 0.5 mU/L	<0.1 mU/L	0.1 to 0.5 mU/L

Tg: thyroglobulin; WBS: whole-body scan; RAI: radioiodine; MRI: magnetic resonance imaging; CT: computed tomography; FDG-PET: fludeoxyglucose-positron emission tomography; TSH: thyroid-stimulating hormone.
* Consider if nonstimulated Tg is greater than 10 ng/mL or Tg is rising.
¶ TSH goals are modified based on concurrent medical conditions that increase the risk of TSH suppression.

Data from: Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26:1.

Graphic 89724 Version 5.0

خرید پکیج

Differentiated thyroid cancer: Ongoing monitoring